Geovax Labs is a buy, Roth says

Roth Capital sees a big upside for GeoVax after the company released promising new vaccine data.

GeoVax Labs (GeoVax Labs Stock Quote, Chart, News, Analysts, Financials NSQ:GOVX) received a “Buy” rating and a $18.00 12-month price target from Roth Capital Partners analyst Jonathan Aschoff following new clinical data that supports further development of the company’s lead COVID-19 vaccine.

GeoVax presented new Phase 2 data for its COVID-19 vaccine, GEO-CM04S1, at the 25th Annual World Vaccine Congress on April 24. GeoVax said the vaccine showed strong immune responses across multiple Phase 2 trials, including in healthy adults and immunocompromised patients, with robust antibody and T-cell responses and no significant safety issues.

“The data underscore the value of our dual-antigen approach, particularly for patients underserved by existing single-antigen vaccines,” GeoVax’s Don J. Diamond said. “GEO-CM04S1 not only drives strong antibody and T cell immunity in healthy adults but also in the immunocompromised, a population historically underserved by single-antigen mRNA vaccines.”

In his April 28 equity research report, Aschoff says the results strengthen the case for GeoVax’s differentiated multi-antigen approach to COVID-19 vaccination.

“GEO-CM04S1’s potency across trials, especially in immunocompromised subjects, supports the vaccine’s continued development and highlights its potential advantages over single-antigen COVID-19 vaccines,” Aschoff wrote.

He thinks that GeoVax will generate $0.8-million in revenue in fiscal 2025 and $0.0-million in revenue in fiscal 2026. The analyst thinks the company will report an operating loss for 2025 of $(29.4)-million, and a loss of $(35.1)-million in 2026.

Aschoff added that GeoVax’s multi-antigen vaccine could become a valuable option for patient groups where existing vaccines underperform, strengthening its commercial prospects.

He outlined factors that could prevent Roth’s price target from being reached, including setbacks or failures in clinical trials, failure to obtain regulatory approval for pipeline candidates and a smaller-than-expected commercial opportunity caused by shifts in market size, increased competition or changes in product pricing and reimbursement.

-30-